Credelio Plus
lotilaner / milbemycin oxime
Table of contents
Overview
Credelio Plus is a veterinary medicine used in dogs to treat concurrent infestations with parasites living outside (ticks and/or fleas) and inside (worms) the animal's body. The medicine can be used as part of the management of flea allergy dermatitis (an allergic reaction to flea bites).
Credelio Plus contains the active substances lotilaner and milbemycin oxime.
Authorisation details
Product details | |
---|---|
Name |
Credelio Plus
|
Agency product number |
EMEA/V/C/005325
|
Active substance |
|
International non-proprietary name (INN) or common name |
lotilaner / milbemycin oxime
|
Species |
Dogs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QP54AB51
|
Publication details | |
---|---|
Marketing-authorisation holder |
Elanco GmbH
|
Date of issue of marketing authorisation valid throughout the European Union |
14/04/2021
|
Contact address |
Heinz-Lohmann-Str 4 |
Product information
14/04/2021 Credelio Plus - EMEA/V/C/005325 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Endectocides
Therapeutic indication
For use in dogs with, or at risk from, mixed infestations/infections of ticks, fleas, gastrointestinal nematodes, heartworm and/or lungworm.